The Penn Center for Precision Medicine (PCPM) works to enhance the development of precision medicine efforts, as well as implement precision-medicine-based clinical care in the fabric of routine care.
We hope to forge strong interconnections between the people who are making impactful scientific discoveries every day and the clinicians and clinical teams delivering outstanding care. We also serve as a source of information for both programs and centers within the health system and for organizations outside that wish to explore partnerships with us.
To accomplish these goals and advance precision medicine, we have the following four initiatives in place:
We bring together an interdisciplinary team with expertise in data analysis, biostatistics and health economics to allow us to measure both biological (medical) and economic (cost and cost avoidance) outcomes. These measurements will be critical to evaluate the success of our efforts.
Build Infrastructure to Maximize Synergies
We’re building a structure that will better integrate efforts, break up silos and achieve more synergy. This infrastructure includes:
- A fellows program to help faculty leaders vet and develop precision medicine projects
- Two assistant directors tasked with bringing clinicians, physician-scientists and researchers together
- An “accelerator fund”, designed to support projects that test novel, interdisciplinary precision medicine approaches that directly impact patient care
- A translational innovation laboratory to help us continuously innovate and accelerate the translation and validation of cutting-edge diagnostic technology
Integrate Precision Medicine in Patient Care
Our biggest goal is to translate the advances in precision medicine into daily care for our patients. We’re employing “demonstration projects” to bring precision medicine into routine patient operations and measure their impact.
Present an Outward-Facing Presence
We’ll communicate Penn’s leadership in precision medicine to internal staff and to the broader public via online and social media outreach and an annual symposium.
Request for Applications
Penn Center for Precision Medicine Accelerator Fund Projects
The PCPM Accelerator Fund is currently seeking requests for application that will accelerate development of precision medicine efforts at Penn and help to implement precision medicine-based clinical care in the fabric of routine care provided by the health system.
The PCPM welcomes all applications that focus on bringing a particular precision medicine approach to clinical care. Project descriptions should be supported by preliminary data demonstrating the viability of the approach under laboratory conditions. Please note that for purposes of this process, “precision medicine” is broadly defined, and includes a variety of approaches to phenotype patients and personalized care (including genetics, genomics, other ‘omics, biomarkers, imaging, computational approaches, wearable devices, etc.)
Review Criteria will include:
- Impact: What is the likelihood that the proposed program of will translate precision medicine based approaches to clinical practice and have a transformative impact on patient care?
- Impact on Penn Medicine: How will this project impact the delivery of patient care and/or health economics across Penn Medicine?
- Innovation: Is the proposal creative and original? If successful, will the work produce dramatic shifts in clinical practice, improving our ability to deliver individualized care by using novel concepts, methodologies, and/or interventions? Will the innovation help to decrease health care costs?
- Investigative Team: Do the proposed PIs have a strong track record of leadership of interdisciplinary and translational science? Does the team have sufficient interdisciplinary breadth and depth to carry out the proposed research?
- Approach: Are the general strategies and translational approaches sufficiently rigorous to ensure generation clinical efficacy, financial cost/opportunity data? Are reasonable metrics of success articulated?
Presubmission inquiries about proposals are welcome; please put “precision medicine proposal” in the title of your email (mailto:email@example.com).
- Please refer to the detailed application guidelines (PDF).
- Submit detailed Letter of Intent to the Chief Administrative Officer of the Penn Center for Precision Medicine, Joshua Lubin, at firstname.lastname@example.org by February 1, 2017 by 5 PM
Welcome Joshua Lubin, MBA
The Penn Center for Precision Medicine (PCPM) is pleased to announce the appointment of Joshua Lubin, MBA, as Chief Administrative Officer of the newly established PCPM. In this capacity, he will work closely with David B. Roth, MD, PhD, Director of the Penn Center for Precision Medicine, and the many stakeholders invested in this field to accelerate the implementation of precision medicine into clinical care.
Joshua Lubin has extensive experience in medical school administration, research administration, and healthcare administration. He most recently served as Director of Operations and then Chief Operating Officer at the Rowan University School of Osteopathic Medicine (formerly UMDNJ). Prior to Rowan University, he held successive managerial and leadership positions at Thomas Jefferson University Hospitals, including Administrator at the Kimmel Cancer Center, where he was responsible for the financial and operational oversight for three departments, including two wet-bench research departments, one clinical research division, and 12 research core facilities, as Research Administrator at the Office of Research Administration, and as Hospital Grants Administrator, where he was responsible for the pre- and post-award administration of large grants for both clinicians and clinical trials and for basic scientists. He received his Master of Business Administration with a focus on health, health-care administration, and management from Rosemont College in 2006 and is a member of the American College of Healthcare Executives (ACHE).
Joshua Lubin will have overall responsibility for the successful development, implementation and advancement of the operational, strategic, and programmatic initiatives of the PCPM, interfacing between the research environment at the School of Medicine and project implementation in the context of the clinical enterprise with a varied set of stakeholders across UPHS. We are delighted to have him on board.
Welcome Abigail Tripp Berman, MD, MSCE
The Penn Center for Precision Medicine (PCPM) is pleased to announce the appointment of Abigail Tripp Berman, MD, MSCE, Assistant Professor of Radiation Oncology, as Associate Director, Clinical, of the newly established PCPM. In this capacity, she will work closely with David B. Roth, MD, PhD, Director of the Penn Center for Precision Medicine, and the many stakeholders invested in this field to accelerate the implementation of precision medicine into clinical care.
Dr. Berman earned her A.B. in Chemistry at Harvard University, and her Medical Degree and Masters of Science in Clinical Epidemiology at the Perelman School of Medicine at the University of Pennsylvania. She completed her medicine internship and radiation oncology residency at the University of Pennsylvania. She specializes in the treatment of patients with lung cancer and other thoracic malignancies with photon and proton radiation therapy and has research expertise in translational thoracic radiation oncology and clinical trials with multi-modality therapy. Dr. Berman has received research funding from the National Institutes of Health and the Radiologic Society of North America. She is the director of the medical student Radiation Oncology clerkship and Co-Director of Clinical Trials in Oncology Course and Workshop. She is a member of the ITMIG Thymic Carcinoma Workgroup and on the Editorial Board of RadOnc Questions and Frontiers in Oncology.
The PCPM was developed by Dr. Roth and senior leaders at Penn Medicine to create and implement precision medicine-based clinical care pathways embedded in systems of care and to facilitate practice-changing research by making robust connections between various groups working at Penn. The PCPM will implement accelerator fund and implementation projects to bring precision medicine into routine UPHS operations and measure their impact. The PCPM has broad support from the EVP/Dean and PSOM leadership.
In her role as Associate Director, Clinical, Dr. Berman will be responsible for helping to create and sustain robust interfaces between clinicians and their clinical needs and those of basic or translational researchers. She will help the PCPM develop and actualize the implementation projects vetted by the Internal Advisory Board and others into clinical operations of the Health System and will work with the PCPM’s Outcomes Measurement team and other team members to monitor other precision-medicine projects, including those funded by the accelerator fund.
We are certain that Dr. Berman’s drive, commitment and vision will continue to energize the faculty and help Penn and the PCPM to achieve national preeminence in the rapidly expanding field of precision medicine.
David B. Roth, MD, PhD
Simon Flexner Professor and Chair of Pathology and Laboratory Medicine
Director, Penn Center for Precision Medicine
University of Pennsylvania Perelman School of Medicine